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Surgical correction of congenital cardiac malformations or aortocoronary bypass surgery
in many cases implies the use of cardiopulmonary-bypass (CPB). However, a possible
negative impact of CPB on internal organs such as brain, kidney, lung and liver
cannot be neglected. In general, CPB initiates a systemic inflammatory response
(SIRS) which is presumably caused by contact of blood components with the surface
of CPB tubing. Moreover, during CPB the heart typically undergoes a period of
cold ischemia, and the other peripheral organs a global low flow hypoperfusion.
As a result, a plethora of pro-inflammatory mediators and cytokines is released
activating different biochemical pathways, which finally may result in the occurrence of
microthrombosis, microemboli, in depletion of coagulation factors and haemorrhagic
diathesis besides typical ischemia-reperfusion injuries. In our review we will focus on
possible pharmacological interventions in patients to decrease negative effects of CPB
and to improve post-operative outcome with regard to heart and other organs like brain,
kidney, or lung.
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INTRODUCTION
At the beginning of the twentieth century most of the inborn cardiac malformations could not be
operated due to the absence of a medical device for body perfusion during open heart surgery.
In 1885 two physicians invented a “respiration system” which could be considered as a first
prototype of a heart-lung machine: Maximilian von Frey and his colleague Max Gruber both
working at the Carl-Ludwig Institute in Leipzig developed a machine capable of perfusing and
oxygenating isolated organs (von Frey and Gruber, 1885). However, this machine was intended to
be used for basic research and not for open heart operations. Nearly, 70 years later in 1954 Gibbon
designed a device which was able to bypass heart and lung and he also was the first cardiac surgeon
who used it during open heart operations (Gibbon, 1954). This heart-lung machine -the so-called
cardiopulmonary bypass (CPB)—was a milestone in cardiac surgery together with the development
of surface hypothermia by Bigelow (1954). Both medical developments were a tremendous step for
heart operations and the onset of our modern cardiac surgery. Although the heart-lung machine
has now become indispensable and allows very complex heart operations such as the correction
of inborn cardiac diseases like Morbus Fallot or the hypoplastic left heart syndrome, the potential
adverse effects of this technique on sensitive organs like brain or kidney cannot be ignored. In
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particular, in children there are several reports on negative effects
of the cardiopulmonary bypass (CPB) on the developing brain
with some of the cerebral areas including the hippocampus being
especially sensitive to ischemia and reperfusion injury (Chugani,
1998). It is a well-known fact that lesions in the hippocampus,
which is involved in learning and memory processes, might
lead to cognitive impairments like learning disabilities, memory
deficits, behavioral disorders, and hyperactivity (Su and Undar,
2010). Despite the fact that neurological assessment is inherently
difficult in neonates and small children there are several
lines of evidence that the potential adverse effects of CPB
on the developing brain are subtle and that neurological
deficits manifest themselves often years after successful surgical
correction (Pua and Bissonnette, 1998). In fact, there are some
clinical studies on children with complex cardiac malformations
operated in early childhood, which showed that CPB might
have negative implications on the later neurological outcome
(Calderon et al., 2010; Bellinger et al., 2011).
The flow generated by the heart-lung machine usually has
a constant and mostly laminar flow profile. This is in contrast
to our own cardiovascular system which produces a pulsatile
blood flow. This should not have a negative impact on cerebral
perfusion as -due to autoregulative processes (Bayliss-effect)—
cerebral perfusion remains constant within a wide pressure range
(50–150mmHg) (Bayliss, 1902). However, there is some evidence
that a more physiological pulsatile flow might be superior over
the commonly used non-pulsatile flow during CPB (Kusch et al.,
2001). Other organs like kidney, liver, and intestine are less tightly
autoregulated, and thus also possibly affected by CPB, especially
in young organisms (Tirilomis et al., 2009, 2013; Doguet et al.,
2012).
However, more than two-thirds of all cardiac surgical
procedures do not involve inborn cardiac malformations in the
young but aortocoronary bypass grafts and valve replacements in
elderly patients. These patients also have a substantial probability
to develop severe impairments like neurological complications
(disorientation, transient ischemic attacks, and stroke), renal
failure with the necessity of dialysis, or lung disorders with
prolonged artificial ventilation (Alexander et al., 2000; Boldt et al.,
2003; Reis Miranda et al., 2005; Kamiya et al., 2014). It should
be mentioned that stroke and TIA may be attributed to clots
embolizing the A. cerebri media area and disorientation probably
is the consequence of global low flow ischemia affecting the
water-shed region of hippocampus.
It seems to be remarkable that despite an appropriate “cardiac
output” delivered by the heart-lung-machine and body cooling,
organ injuries develop, which impair the post-operative result.
Moreover, both bypassed organs -heart and lung- are burdened
with ischemia and reperfusion injury, which also has a negative
impact on the post-operative outcome (Royster, 1993; Slottosch
et al., 2014).
In general, CPB initiates a systemic inflammatory response
(SIRS) which is presumably caused by contact of blood
components with the surface of CPB tubing. As a result,
leucocytes, monocytes, endothelial cells, platelets and the
complement system are activated, which subsequently lead to
a release of a plethora of pro-inflammatory mediators and
cytokines. The activation of different biochemical pathways may
result in the occurrence of microthrombosis, microemboli, in
depletion of coagulation factors and haemorrhagic diathesis
(Murphy and Angelini, 2004).
On the cellular level ischemia and reperfusion induce
several signaling cascades including translocation of numerous
transcription factors [for example: HIF1α (hypoxia-induced
factor 1α) or AIF (apoptosis inducing factor)], induction
of caspase pathway, activation of matrix-metalloproteinases
(MMPs), PARP-activation (poly-ADP-ribose polymerase), and
formation of reactive oxygen and nitrogen species (Salvesen,
2002; Ye et al., 2002; Yu et al., 2006; Smith et al., 2008; Lange
et al., 2010). These signaling cascades are involved in regulatory
mechanism of cell survival and cell death finally leading to
potential organ dysfunction.
In the past decades several protecting strategies have been
applied to ensure greater safety during CPB: bubble traps and
screen filters to reduce the risk of embolization, lung protective
mechanical ventilation to avoid respiratory distress syndromes,
improved pH, temperature and fluidmanagement, and a pulsatile
flow (which has been shown to improve renal function and
regional oxygen saturation of the brain) or pharmacological
approaches to minimize organ damage (Zhao et al., 2011; De
Somer, 2013; Ferrando et al., 2015; Nam et al., 2015). Various
drugs have been tested -mostly in various animal models-
to reduce organ malfunction: drugs targeting the Na+/H+-
exchanger or the IKATP channel, inhibitors of MMPs, PARP-
inhibitors, antioxidants, guanylyl cyclase stimulators, or anti-
inflammatory drugs.
In our review we will focus on possible pharmacological
interventions in patients to decrease negative effects of CPB and
to improve post-operative outcome with regard to heart and
other organs like brain, kidney, or lung.
PARP-Inhibitors
DNA-strand breaks mainly occur during the reperfusion phase
when oxygen levels increase. Reactive oxygen species (ROS) and
peroxynitrite (which is formed in the presence of NO) diffuse
into the nucleus and induce disruption of the genetic material.
The resulting single strand DNA nicks are detected by PARP and
labeled with PAR-chains. These in turn are a signal for other DNA
repairing enzymes such as DNA ligase and DNA polymerase beta
(Isabelle et al., 2010). After the repair PAR-chains are degraded.
Over-activation of PARP depletes NAD+ (nicotinamide adenine
dinucleotide) stores and finally leads to a reduction of ATP-
levels, which at the end is disastrous for the cell. Moreover, PAR-
chains cause release of AIF (apoptosis-inducing factor) from
the mitochondria into the cytoplasm. AIF then translocates into
the nucleus and initiates the so-called parthanatos, which is
irreversible and results in cell death (Wang et al., 2009).
Inhibitors of the PARP-pathway such as minocycline might
prevent from ATP-depletion and might maintain intracellular
ATP-content. Minocycline is a broad spectrum antibiotic
attributed to tetracycline class. It has bacteriostatic effects and
is frequently used for treatment of acne vulgaris or Lyme’s
disease. Moreover, it has neuroprotective and anti-inflammatory
properties (Giuliani et al., 2005; Kim and Suh, 2009). In a
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rat model of hypothermic cardiac arrest Drabek et al. (2014)
could demonstrate that minocycline reduced ischemia-induced
elevated TNFα-levels in the brain (Drabek et al., 2014). The same
effect could be shown in liver, where minocycline significantly
decreased hepatic TNFα and IL-1β expression and improved
liver function (Li et al., 2015). The PARP-inhibitory effect of
minocycline and its positive influence on cell apoptosis were
also revealed in other studies and by our working group:
piglets subjected to cardio-pulmonary bypass showed less organ
dysfunction (hippocampus, liver, kidney) when minocycline was
administered before bypass and during reperfusion (Tao et al.,
2010; Dhein et al., 2015; Salameh et al., 2015).
The typical plasma concentration in patients receiving
minocycline treatment for medical reasons is in the range
of 1–2µmol/L (Sakellari et al., 2000). This is more than
ten times higher than the reported concentration needed
for sufficient PARP-inhibition (Alano et al., 2006). It seems
reasonable to consider minocycline application during cardio-
pulmonary bypass in clinical settings, but at the moment patient
studies to corroborate the protective effects of minocycline are
missing. Another tetracycline with a similar chemical structure
as minocycline is doxycycline and there is evidence that this
tetracycline derivate also has cytoprotective activities. According
to a study of Schwartz et al. (2013) the cytoprotective effects
of both tetracycline derivatives are exclusively confined to
them, as other derivatives tested did not show any positive
effects in ischemia/reperfusion injury. The mechanism by
which the protection is obtained is not very clear but it was
proposed that inhibition of theMPT (mitochondrial permeability
transition) pores is responsible for improved cell survival.
Another interesting feature of doxycycline is its activity against
matrix metalloproteinases (MMPs), which is described below.
A wide range of other PARP-inhibitors has been used
mainly in basic research. In animal or cellular models 3-
aminobenzamide, PJ34, or INO-1001 have been tested in
ischemia and reperfusion and it has been found that these
pharmaceuticals are very effective in blocking PARP. However,
until now large clinical trials have not been carried out.
3-aminobenzamide was among the first PARP-inhibitors
and was described in the eighties to inhibit PARP by about
90% in an in vitro assay (Purnell and Whish, 1980). In the
following years 3-aminopenzamide was used in experimental
models of stroke, renal ischemia, myocardial infarction, or heart
transplantation and it was found that in all cases application of 3-
aminobenzamide prior to cellular injury led to a better outcome
of the examined organs (Chatterjee et al., 2000; Liaudet et al.,
2001; Fiorillo et al., 2003; Koh et al., 2005). In a more recent
study 3-aminobenzamide was tested in a rabbit model of CPB
(Yeh et al., 2006). The authors could demonstrate that PARP-
inhibition resulted in a significant decrease in cytokine levels
and as a consequence a reduction of ROS, which in turn led
to less apoptosis of cardiomyocytes and to improved contractile
function of the hearts.
Another well-known PARP-inhibitor is PJ34. It is classified
as a phenanthridinone and besides its PARP-inhibiting activity
it exhibits also antiviral and anti-tumorous functions (Lin et al.,
2014; Liang et al., 2015). Additionally, Szabo et al. (2004a,b)
and Andrasi et al. (2005), demonstrated in a canine model of
CPB that administration of PJ34 was able to significantly reduce
endothelial dysfunction of mesenteric vessels (frequently seen
after CPB). Moreover, it improved myocardial contraction and
even pulmonary function.
A similar profile of action is attributed to INO-1001, which
showed cardioprotective and lung protective properties in a
canine model of cardiopulmonary bypass injury and also seemed
to diminish mesenteric dysfunction as described by the same
working group (Szabo et al., 2004c,d). In another study of
Dhein et al. (2008) piglets of up to 10 kg were examined in a
model of extracorporeal circulation and it was found that the
post-ischemic elevated TNFα (tumor necrosis factor α)- and
HSP70 (heat shock protein 70)-levels as well as lung impairment
were significantly reduced by INO-1001 pre-treatment. Because
of promising results in basic research a clinical trial was
initiated involving patients with acute myocardial infarction
undergoing percutaneous transluminal coronary angioplasty
(Ekblad et al., 2013). In these patients INO-1001 seemed to
decrease inflammatory reactions during recovery. However,
frequently seen non-serious adverse events were described:
elevation of liver enzymes, nausea, vomiting, and increased QTc
(corrected QT-time; Morrow et al., 2009). This might be the
reason why more detailed investigations on possibly protective
effects of INO-1001 on the heart during ischemia and reperfusion
were not continued in patients.
While in anti-cancer therapy PARP-inhibitors are still
investigated in ongoing studies there are so far no human studies
in organ protection during CPB. This might be due to the
unfavorable side effects.
MMP-Inhibitors
A collagenolytic factor was first discovered 1962 by Gross
and Lapiere when they investigated how tadpoles lose their
tails during metamorphosis (Gross and Lapiere, 1962). This
factor was later named MMP-1 and to date more than 20
different MMPs are discovered. The MMPs are zinc-dependent
endoproteinases involved in the degradation of extracellular
matrix, in the cleavage of cell surface receptors and in
the regulation of proliferation, cell apoptosis and migration.
Moreover, they influence cytokine processing for example
activation of TNFα or IL-1β, thereby modulating leucocyte
recruitment and inflammatory processes (Van Lint and Libert,
2007). A variety of cardiovascular diseases are related to a
dysfunction of MMPs: the development of aortic aneurysms
which was ascribed to aMMP-17 deficiency, or an over activation
of MMP-2, plaque vulnerability in patients with angina pectoris,
as well as impaired wound healing in patients suffering from
diabetes mellitus (Chen et al., 2015b; Martin-Alonso et al.,
2015; Uccioli et al., 2015; Wang et al., 2015). Opponents of the
MMPs are the TIMPs (tissue inhibitors of metalloproteinases)
from which four different inhibitors are known. Interestingly,
very recently in a meta-analysis of thoracic aortic aneurysms
the expression of MMP-2, MMP-9 and the relation of these
proteinases to TIMP-1 and TIMP-2 were analyzed and it was
found that thoracic aortic aneurysms with bicuspid aortic valves
had a different expression pattern ofMMPs and TIMPs compared
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to aortic aneurysms with tricuspid aortic valves (Rabkin, 2014).
Since, MMPs also play a role in inflammation and cytokine
production it was not far to seek for a role of MMPs during
CPB. Indeed, it was detected that after CPB plasmaMMP-9 levels
were significantly elevated reaching control levels after about
24 h. As a consequence leucocyte counts were also increased.
However, as described in the patient trial of Lin et al. (2015) this
was not associated with bypass time or pulmonary dysfunction.
In contrast, another patient trial showed that elevated MMP-8
and MMP-9 levels are associated with impaired oxygenation and
pulmonary dysfunction after CPB (Beer et al., 2015). Thus it may
be of interest to inhibit MMPs during CPB.
As mentioned above some of the tetracyclines are potent
MMP-inhibitors, these are minocycline, doxycycline and
oxytetracycline (Schwartz et al., 2013). In some animal studies
doxycycline was very effective in reducing MMP-9-, TNFα-,
and IL-1β-levels and it also showed protective effects on lung
damage after CPB (Wang et al., 2014; Zhang et al., 2014).
Decreased TNFα-levels in the brain were also found by Drabek
et al. (2014), attributed to minocycline application prior to
hypothermic cardiac arrest in rats. Thus, one could conclude
that this also might be due to MMP-inhibition by minocycline
although in their study MMP-levels have not been measured.
Another mechanism was proposed by Schwartz et al. (2013), who
demonstrated in a study on hepatocytes exposed to simulated
ischemia and reperfusion that minocycline and doxycycline
inhibited cellular death by suppression of MPT and not by
MMP-inhibition.
Most of the MMP-inhibitors have only been examined in
animal models as they are not approved for human medical
treatment. Thus, despite extensive pre-clinical research up to date
there is no MMP-inhibitor tested in clinical trials which holds
promise for effective medication in patients.
In summary, blocking of MMPs is a very useful tool in
organoprotection during CPB, but until now there is no MMP-
inhibitor “in the pipeline” to effectively protect organs during
CPB in a clinical setting. Since, doxycycline, minocycline, and
oxycycline are approved drugs—although the application of these
medicaments during CPB would be an “off-label use”—it might
be worth to set up clinical trials to investigate the potential of this
medication during CPB.
Inhibitor of Na+/H+-Exchanger (NHE)
Ischemic or hypoxic conditions lead to intracellular acidosis,
resulting in an activation of several transmembrane ion pumps
with the aim to regain normal intracellular pH. The following
membrane transporters are involved in this process: intracellular
acidification activates the NHE which exchanges H+ ions against
Na+. This would increase intracellular pH but finally will lead to
an undesirable increase in intracellular sodium. Additionally, due
to a dropdown in ATP, Na+/K+-ATPase (which under normal
conditions maintains transmembrane sodium and potassium
gradients) is inhibited which also contributes to the elevated
sodium levels. Furthermore, low pH activates the Na+/HCO−3
symporter, which carries NaHCO3 into the cell to buffer excess
H+ ions (Lagadic-Gossmann et al., 1992). This process also
leads to an accumulation of intracellular Na+ which at the end
stimulates the Na+/Ca2+ exchanger to extrude sodium against
calcium. Enhanced intracellular calcium levels on the other hand
are a known trigger to finally induce cellular death (Garcia-
Dorado et al., 2012).
In the mammalian heart the NHE-1 is the predominant
isoform and it has been found that its blockade is beneficial
during ischemia and reperfusion injury. It has been demonstrated
in a Langendorff heart preparation that inhibition of the NHE-
1 with cariporide led to significant fewer alterations in cardiac
hemodynamics, a lower incidence of ventricular fibrillation and
a less pronounced decrease in intracellular ATP (Dhein et al.,
1998). The same working group could also show that intracellular
acidification of isolated guinea pig myocardial cells resulted
in a significant increase in sodium, which was even more
pronounced in NaHCO3 containing Tyrode’s solution (Salameh
et al., 2002). Cariporide prevented from this increase in sodium
quite efficiently. Surprisingly, a rise in intracellular calcium was
not seen and it was speculated that this was due to the inhibitory
effect of H+ ions on the Na+/Ca2+ exchanger (Doering et al.,
1996). Thus, inhibition of NHE-1 seems to be a favorable tool
to protect the myocardium during ischemic processes. Indeed,
several animal studies with simulated CPB have proven that
cariporide and its kindred zoniporide was very effective in
cardiac protection and additionally led to improved neurological
outcome (Clements-Jewery et al., 2004; Liakopoulos et al.,
2011). Moreover, in a model of orthotopic heart transplantation
cariporide led to a better ventricular recovery (Martin et al.,
1998). Another study group came to the same conclusion. In
their heart transplantation experiments they could demonstrate
that cariporide significantly better preserved the donor hearts
with lower levels of troponin I as compared to the control group
without cariporide (Ryan et al., 2003). However, the positive
results with NHE-inhibition in ischemic hearts could not be
transferred to other organs: in a study with pigs undergoing CPB
an improvement of the disturbed lung function was not seen.
The experimental group receiving cariporide was even worse
compared to the control group (Eichler et al., 2004). One may
assume that in these organs NHE may be missing or other
subtypes of NHE may be expressed.
In the Guardian trial with nearly 3000 patients undergoing
coronary artery bypass surgery cariporide at the highest dose of
120mg led to a significant reduction in death and myocardial
infarction (Theroux et al., 2000). The other doses tested (20
and 80 mg) had no beneficial effects neither on death nor on
myocardial infarction. In a subsequent study of Scholz et al.
(2003) 53 high risk patients out of the Guardian study population
were included, who either received 20, 80, or 120mg cariporide,
respectively. Blood samples were taken prior to coronary artery
bypass operation and 1 h after surgery and serum S-100B
levels were measured. S-100B proteins have been found to be
an excellent marker for neuronal damage as elevated plasma
levels are positively correlated with neuropathological conditions
(Zongo et al., 2012). Scholz and co-workers demonstrated that
CPB elevated S-100B serum concentration by more than six-
fold over the pre-operative status. Cariporide -in all three doses
tested—was effective in significantly lowering S-100B levels, in
the highest dose to nearly pre-operative levels. However, overall
Frontiers in Pharmacology | www.frontiersin.org 4 December 2015 | Volume 6 | Article 296
Salameh and Dhein Pharmacological Organoprotection during Extracorporeal Circulation
postoperative outcome was not influenced probably partially due
to the small number of patients per group.
MPT-Inhibitors
Mitochondria—the power stations of cells—are essential for cell
survival, since they produce the global energy supplier ATP
via the respiratory chain. During several pathophysiological
processes such as traumata, ischemia, neurodegeneration, or
Reye-syndrome mitochondria might be damaged and undergo
a transition of permeability. That means that the mitochondria
lose their impermeability by opening the so-called permeability
transition pore (MPTP; Lemasters et al., 2009). This pore was
first discovered by Hunter et al. (1976) who described a process
induced by calcium ions during which the permeability of
the inner mitochondrial membrane increased, which resulted
in mitochondrial swelling, loss in transmembrane potential
and ATP, AIF-release and finally in cell death. Other factors,
which induce MPT are free radicals, fatty acids or inorganic
phosphate (Nicholls and Brand, 1980; Garcia-Ruiz et al., 2000;
Honda and Ping, 2006). However, calcium ions seem to be
important for opening of MPTP. Regarding the heart, during
myocardial infarction intracellular calcium ions rise inducing
calcium overload, hypercontraction of cardiac cells and cell death
(Garcia-Dorado et al., 2012). Thus, blocking of the MPTP might
be a useful tool to inhibit the deleterious effects of permeability
transition. In a small trial Piot et al. (2008) described a reduced
infarct size in patients with acute myocardial infarction who were
treated with cyclosporine before PCI. However, larger trials to
confirm these results are not available.
In a recently published patient trial Hausenloy et al. (2014)
reported on reduced troponin T levels in patients undergoing
CPB, who were treated with cyclosporine prior to bypass.
Especially, in high risk patients with longer clamping times
cyclosporine treatment seems to be advantageous. Moreover,
there are several animal studies suggesting that the addition of
cyclosporine to the cardioplegic solution is beneficial for heart
protection in the sense that hearts treated with cyclosporine
recovered faster, had lower malondialdehyde levels, lower levels
of pro-apoptotic factors and less mitochondrial alterations (Oka
et al., 2008; Pritzwald-Stegmann et al., 2011).
Another promising MPT-inhibitor is the amino-acid-like
substance taurine (2-aminoethanesulfonic acid). Taurine is
typically found in high concentrations in cardiac and skeletal
muscle, retina and central nervous system. Some positive
biological actions have been ascribed to taurine: antiarrhythmic
activities, positive inotropic functions, antioxidant properties,
prevention of myocardial calcium overload, which occurs after
ischemia/reperfusion injury and inhibition of mitochondrial
swelling by preventing MPTP to open (Ueno et al., 2007; Chen
et al., 2009). Thus, the administration of taurine might be a useful
possibility to minimize cardiac damage during CPB (Schaffer
et al., 2014). In a patient trial of Milei et al. (1992) with 12
patients, six of them receiving taurine prior to surgery bypass
vs. six without, was found in cardiac biopsies that the taurine
supplemented hearts exhibited less lipid peroxide formation,
less mitochondrial damage and hence less necrotic myocardial
cells. This could also be verified in several animal studies
(Oriyanhan et al., 2005; Sahin et al., 2011). Additionally, Ueno
et al. (2007) demonstrated that not only biochemical parameters
were significantly lower (i.e., creatine kinase, lipid peroxide) in
hearts treated with taurine but also heart function itself was
significantly improved (i.e., left ventricular systolic and diastolic
pressure, rate of pressure increase and decrease). Thus, taurine
application might be beneficial during cardiac surgery but larger
clinical trials to evaluate the protective potential of taurine are
missing. Similarly, data on taurine effects in CPB on other organs
like brain, lung or kidney are not available.
As mentioned above the tetracycline derivative minocycline
has the ability to inhibit calcium-induced mitochondrial
swelling during ischemia/reperfusion. In an animal model
of orthotopic liver transplantation Theruvath et al. (2008)
demonstrated the effective blockade of MPT by minocycline
and NIM811 (N-methyl-4-isoleucine cyclosporine) but not by
tetracycline itself. The mechanism proposed was the inhibition
of the calcium-induced MPT opening, mitochondrial swelling
and depolarization which led to a collapse of oxidative
phosphorylation and cell necrosis. However, this particular
“side-effect” of minocycline seems to be cell type dependent
and also dependent on the applied minocycline concentration.
In mitochondria from brain and spinal cord minocycline
significantly inhibited mitochondrial swelling and calcium-
uptake at high doses whereas at lower concentrations it
almost increased the swelling response to elevated calcium
levels (Mansson et al., 2007). Thus, the exact mechanism of
how minocycline exerts its protective effects still needs to be
unraveled.
Antioxidants
ROS i.e., peroxide, superoxide or hydroxyl radicals are
physiologically formed during oxidative phosphorylation
within the mitochondria. Usually, cells are capable to protect
themselves by neutralizing these endogenous ROS. However,
if oxidative stress overwhelms cellular protective mechanisms
initiation of apoptosis may result (Zakkar et al., 2015). CPB is one
of the known exogenous factors which cause inflammation and
oxidative stress. It is widely accepted that oxygen radicals have
a significant negative impact on cell integrity during ischemia
and reperfusion. Thus, anti-oxidative additives might be helpful
during CPB.
The 2-phenyl-1,2-benzisoselenazol-3(2H)-one ebselen, a
selene derivative, has been found to significantly improve the
neurological outcome in stroke patients, when ebselen was
applied early after onset of stroke (Yamaguchi et al., 1998).
In a piglet bypass model with 120min aortic clamping Chen
et al. (2015a) tested the effect of ebselen on cardiac protection.
They found that addition of ebselen to the cardioplegic solution
led to a significantly improved cardiac recovery with less
cardiomyocyte apoptosis and better preserved mitochondrial
morphology. Similar results were reported by Cabigas et al.
(2012) in their study on isolated rabbit hearts perfused according
to Langendorff.
Another interesting family of drugs are the antioxidant
ingredients of black and green tea, with green tea possessing
higher antioxidative properties than black tea. In an in vivo
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study in man Serafini et al. (1996) could demonstrate that after
ingestion of green tea blood antioxidant capacities increased for
about 60min. The gallate of epigallocatechin (epigallocatechin-
3-gallate, EGCG)—the main ingredient of green tea—was tested
in various experimental settings of inflammation, cancer, and
ischemia. In a rat model of myocardial infarction EGCG was
successful in reducing infarct size and in blocking nuclear
translocation of the transcription factors NF-κB and AP-1
(Aneja et al., 2004). Both factors are negatively associated with
myocardial injury. Moreover, our working group could show in
a piglet model that EGCG significantly reduced kidney damage
and early markers of apoptosis during CPB (Twal et al., 2013).
Our experiments revealed that CPB causes significant swelling of
Bowman’s glomeruli, vacuolization of tubules, loss of energy rich
phosphates, a rise in creatinine and urea and in an increase of
factors of cellular damage. The deleterious effects of CPB could
be prevented by EGCG. In the same model the neuroprotective
potency of EGCG was also tested and we could prove that
hippocampal impairment was less in the experimental group
treated with EGCG (Salameh et al., 2015). However, larger
human trials are required to establish the safety and effectiveness
of EGCG.
N-acetyl-L-cysteine (NAC) is a widely used medicament for
treatment of chronic obstructive lung disease, cystic fibrosis or
paracetamol intoxication. As NAC might act as a scavenger for
oxygen radicals, because of its known antioxidative properties,
it seemed obvious to test this drug during ischemia and
reperfusion injury. In a very recent study with dogs Qu et al.
(2013) could show that CPB is accompanied with severe lung
alterations such as alveolar congestion, neutrophil infiltration,
and thickening of alveolar wall as well as decreased oxygen
index, elevated malondialdehyde concentration and decreased
superoxide dismutase activities. In their study NAC reduced
these morphological and biochemical parameters to control
levels and improved lung function. In a small patient trial Eren
et al. (2003) reported on reduced MDA levels and on lower
alveolar-arterial oxygen gradients in the group treated with
NAC. However, other lung parameters such as lung compliance,
shunt flow, pulmonary vascular resistance and wedge pressure
were not different between the two patient groups (without
or with NAC). Likewise, there was no significant difference in
the clinical outcome of the patients. In another prospective,
randomized, placebo-controlled study including 70 patients with
chronic kidney disease undergoing CPB, NAC was applied up to
the maximal dose starting 2 h before bypass. This trial revealed
that in the NAC receiving group NGAL (neutrophil gelatinase-
associated lipocalin, a marker for acute kidney injury) and ROS
levels were lower compared to the control group without NAC.
Additionally, a significant lower incidence of acute renal failure
in the NAC-receiving group was described (Santana-Santos et al.,
2014). However, in other trials NAC failed to show protective
effects on the kidney (Naughton et al., 2008).
In other patient trials a positive effect of NAC on myocardial
oxidative stress was also demonstrated however a significant
improvement of clinical outcome was not proven (Köksal et al.,
2008; Kurian and Paddikkala, 2010).
IKATP-Openers
ATP-sensitive potassium channels (IKATP) were first discovered
in cardiac cells by Noma (1983), who described an outward
current after a decrease in intracellular ATP. These channels
are found in plasma membrane, sarcolemma, mitochondria, and
nuclei of several cell types i.e., cardiac cells, smooth muscle cells,
pancreas beta-cell, or neurons (Tinker et al., 2014). In the heart
activation of IKATP causes shortening of action potential, thereby
shortening the open state of ICa.L and thus, preventing calcium
overload of the myocardial cells. As calcium overload occurs
during ischemia and contributes to cardiomyocyte damage
and apoptosis IKATP openers could exert protective effects
during ischemia and reperfusion injury. Moreover, an increase
in K+ conductivity may also lead to hyperpolarization of
vascular smooth muscle cells with vasodilatation of coronary
and peripheral arteries. As a consequence peripheral resistance
would decrease and coronary reserve would increase which
finally may facilitate cardiac blood supply and hemodynamics.
In a large randomized, double blind and placebo controlled
trial with over 5000 patients with angina pectoris the IKATP
opener nicorandil showed a significant improvement of outcome
with less myocardial infarction in the nicorandil group (IONA
Study Group, 2004). Moreover, it was found in an animal
study with pigs that nicorandil used together with cold
blood cardioplegic solution preserved myocardial function
better than cold hyperkalemic crystalloid or hyperkalemic
blood cardioplegia (Steensrud et al., 2003). Patient trials with
nicorandil administered during CPB revealed that patients of the
nicorandil group had shorter times to electromechnical arrest
after administration of cardioplegia, lower troponin levels, and
less arrhythmia (Chinnan et al., 2007; Yamamoto et al., 2008).
However, larger trials to confirm these results are missing.
Other IKATP openers like aprikalim were tested on myocardial
cells in culture and it was shown that the addition of aprikalim
during cardioplegic arrest of the cultured cells improved
cardiomyocyte contractile function and led to less calcium
overload (Dorman et al., 1997). Moreover, in a study with piglets
diazoxide a selective mitochondrial IKATP opener preserved
mitochondrial function and morphology after cardioplegic arrest
compared to control hearts. From these measurements the
authors concluded that the preserved mitochondrial function
contributed to the improved myocardial function after CPB in
the diazoxide group (Wang et al., 2006).
In contrast to IKATP openers,IKATP blockers pursue a different
strategy during ischemia and reperfusion: by blocking ATP-
sensitive potassium channels they prevent from potassium
eﬄux which follows ATP-decline and which results in a
decrease in action potential duration and in a spatial dispersion
of repolarization. These electrophysiological inhomogeneities
promote the development of re-entrant arrhythmias (Wilde,
1993). IKATP blockers like the anti-diabetic drug glibenclamide
or the more cardiac specific IKATP blocker HMR1883 have
been found to effectively inhibit ventricular tachycardia after
myocardial infarction in animal models (Dhein et al., 2000;Wirth
et al., 2000). However, during CPB in clinical settings IKATP
blockers have not been tested so far.
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Miscellaneous
Several other pharmacological additives have been tried in
clinical settings to minimize organ dysfunction after CPB.
The β1-selective β-adrenoceptor blocker esmolol is a class
II antiarrhythmic drug which has been developed to treat
supraventricular tachycardia. After intravenous application
esmolol has a short half-life of 9min. It is rapidly hydrolyzed by
plasma esterases, which makes this drug well manageable.
Esmolol has been used during CPB in children and it was
demonstrated that patients of the esmolol group had lower
creatine kinase, troponin I and lactate levels and less need for
inotropic support. Moreover, myocardial structure was better
preserved (Kuhn-Regnier et al., 1999; Gui et al., 2013).
The idea of another study group was to use the anti-oxidative
properties of vitamin E and C during CPB. In a small patient trial
of 20 patients they showed that CPB-caused oxidative stress was
lower in the vitamin treated group. However, whether this was
accompanied by a significant better clinical outcome could not be
proven (Barta et al., 1991). In a more recent study weak beneficial
effects of vitamin E and C application before CPB were found
but again significant positive effects on patient outcome were not
apparent (Gunes et al., 2012). It may be suggested that positive
effects of vitamins partially depend on a pre-existing vitamin
deficit.
Another anti-oxidant substance—coenyme Q10—were used
by Makhija et al. (2008). In their prospective randomized trial,
patients undergoing coronary artery bypass surgery were pre-
treated with Q10 for up to 10 days and clinical outcome was
evaluated. These results revealed that in the Q10 treated group
patients had less arrhythmia, lower need for inotropic support
and shorter in-hospital stays. Thus, it seemed that Q10 may exert
a certain beneficial effect on patient outcome. Similar results with
Q10 have been found earlier by Sunamori et al. (1991), who also
demonstrated that Q10 was effective in preserving left ventricular
function by reducing left ventricular injury. However, the exact
biochemical mechanisms underlying Q10 protection of the heart
remain to be elucidated.
A more recent study published was about the application of
omega-3 polyunsaturated fatty acids, which were given prior
to bypass operation (Veljovic et al., 2013). The results of this
patient trial were as follows: patients in the treatment group had
lower troponin and creatine kinase levels and higher oxygen
extraction compared to the control group. Accordingly, it was
concluded by the study group that omega-3 polyunsaturated
fatty acids might be a useful additive during cardiac
operations.
CPB induces a systemic inflammatory reaction. Thus, the
obvious idea was to suppress inflammation by the application
of corticosteroids. McBride et al. (2004) showed in a small
patient trial that subclinical renal injury was diminished in
the patient group receiving methylprednisolone, although renal
dysfunction could not be prevented. In another study involving
neonates undergoing arterial switch operation dexamethasone
was applied before CPB and levels of inflammatory molecules
were measured in myocardial tissue (Heying et al., 2012). The
results of this trial were in favor of the dexamethasone group
as a certain myocardial protection was seen (lower troponin
levels) with less requirement for catecholamines. In a recently
published comprehensive review of Kristeller et al. (2014)
the advantages and disadvantages of corticosteroids have been
discussed. They evaluated the results of several studies and found
that corticosteroids significantly decreased the incidence of atrial
fibrillation, and when applied in low doses also reduced the
interval of mechanical ventilation. In contrast, higher doses of
corticosteroids had a negative impact on duration of intubation.
Myocardial infarction, stroke, renal failure or mortality were
not significantly diminished by corticosteroids. Since, possible
side effects of corticosteroids such as hyperglycemia, infection,
disturbed wound healing, or gastrointestinal bleeding need
to be taken into account the routine application of these
substances cannot be recommended presently and further
studies are required to evaluate the potential positive effects of
corticosteroids.
Cardioplegic-Solutions
Heart protection during CPB was always a matter of debate as
the heart is not perfused during cardiopulmonary arrest which
means for the cardiac muscle a period of absolute ischemia.
For the survival of myocardial tissue surface cooling is essential
on one hand and induction of cardioplegia on the other hand.
While the previous described manipulations aimed at protection
of both heart and peripheral organs, changes in cardioplegic
solution were primarily designed for organ protection of the
heart.
To achieve cold cardioplegic arrest of the heart several
cardioplegic solutions are in use from which the best known
are the “extracellular” St. Thomas’ Hospital mixture with high
potassium and magnesium and the Bretschneider cardioplegic
solution, the so-called “intracellular” solution with low sodium
and calcium and high potassium. Both crystalloid solutions
are used for cold cardioplegic arrest (Braimbridge et al., 1977;
Bretschneider, 1980). A third one named “Calafiore blood
cardioplegia” is also in clinical use during CPB: oxygenated
blood supplemented with high potassium and magnesium is
administered via the aortic root until cardiac arrest. Calafiori
and co-workers described an advantage of warm blood
cardioplegia versus cold blood cardioplegia in the sense that
myocardium specific enzymes were lower and postoperative
outcome of patients was better in the group receiving warm
blood cardioplegia (Calafiore et al., 1995). Other authors
obtained different results. In a subsequent trial with cold
and warm cardioplegic arrest Pöling et al. (2006) found a
slightly better outcome of patients with cold cardioplegia in
particular in patients with long clamping times. However, the
number of patients in their study was quite small: only 17
patients in each group versus 250 patients in the study of
Calafiore et al. (1995).
In general it can be stated that the question what kind
of cardioplegia -cold, warm, blood, or crystalloid solutions—
might be the best during a specific heart operation is not
resolved until now. Nevertheless, several additives have been
tried to minimize ischemia/reperfusion injury and to better
preserve the energy balance of the heart. In a dog model of
hypothermic cardiac arrest Bretschneider cardioplegic solution
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(=Custodiol) was supplemented with L-arginin, N-α-acetyl-L-
histidine, deferoxamine, and LK-614 (iron chelator) (=Custodiol-
N) and it was demonstrated that the ATP-content was
significantly higher and levels of myeloperoxidase (a marker for
leucocyte activation and inflammation) was significantly lower
in the Custodiol-N group (Veres et al., 2015). Moreover, the
new Custodiol-N solution also showed protective effects with
an improvement of myocardial function in a rat model of
heterotopic heart transplantation. However, the addition of iron
chelators (desferoxamine and LK-614) tended to have a negative
impact on heart protection (Koch et al., 2010). In a model of
failing hearts undergoing CPB a new Bretschneider solution,
developed to preserve the energy level of myocardial cells, was
enriched with amino acids, iron chelators, ketoglutarate, and
saccharose. This solution also exhibited a protective influence on
ATP-levels and cardiac function with an improvement of cardiac
stroke volume and work (Trescher et al., 2013). However, none of
these substances have been administered in a clinical setting and
published controlled patient trials about effectiveness and side
effects are not available. Moreover, while cardiac effects of these
additives have been studied extensively, possible organ protection
of these drugs in other organs (brain, lung, kidney, liver, gut)
often has not been investigated.
SUMMARY
While some decades ago organ protective effects in CPB mainly
aimed at cardioprotection, in recent years the deleterious effects
of CPB on other organs such as kidney, brain, lung, and liver
became more and more in the center of interest. Thus, in
the initial decades scientists and surgeons experimented with
varying cardioplegic solutions and protocols, including pulsatile
flow protocols, hypothermic arrest and warm blood cardioplegia.
More recently, protection of brain, kidney, lung, and liver became
the target of new strategies, often aiming at biochemical processes
activated by ischemia-reperfusion injury associated with CPB.
Thus, it has been shown that CPB acutely induces an ischemia-
reperfusion injury in kidney, lung and brain, which—to different
degrees—can be targeted by PARP-inhibition, MPTP-inhibition,
NHE blockade or anti-oxidative and anti-apoptotic strategies.
There are still many promising substances, which have been
positively tested in ischemia-reperfusion protocols, and which
remain to be evaluated in a clinical or clinical-like CPB-setup.
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